Opexa Therapeutics

From Wikipedia, the free encyclopedia

Opexa Therapeutics NASDAQ: OPXA, formerly known as PharmaFrontiers, is a commercialization-driven biotechnology company that develops autologous cellular therapies for the treatment of multiple sclerosis, congestive heart failure, and diabetes. The company is focused on autologous cellular therapy applications based on its proprietary stem cell and T cell vaccination technologies.

Key products and research include:

• Tovaxin: A novel T cell therapeutic vaccine for multiple sclerosis
• Cardiac stem cell therapy
• Diabetes stem cell therapy

[edit] Location of Operation

Opexa Therapeutics is located in The Woodlands, Texas 30 miles north of Houston, Texas. The company is located in a 10,200 sq. ft. facility that is located on 3 acres in The Woodlands. This location provides space for pipeline development through R & D; a specialized Flow cytometry and Microscopy lab; support of clinical trials with GMP manufacturing Suites; Quality Systems management with Quality Control Laboratory, Regulatory Affairs, Quality Assurance; as well as administrative support space.

[edit] External links

• Opexa Therapeutics Homepage
• BBC Article 3/8/06
• UPI Health Brief